Clinical Trial Update: A Phase II Study of Neoadjuvant Chemotherapy Plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage Ovarian Cancer (TRU-D) [Phase 2]

View source ↗

Summary

Phase II study evaluating neoadjuvant chemotherapy combined with durvalumab and tremelimumab in advanced-stage ovarian cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Yonsei University | Conditions: Ovarian Cancer Stage IIIC, Ovarian Cancer Stage IV | Phase 2 | Status: UNKNOWN